Evolve Private Wealth LLC Has $3.09 Million Holdings in AbbVie Inc. $ABBV

Posted by ABMN Staff on Jun 22nd, 2026

Evolve Private Wealth LLC grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 19.7% in the first quarter, Holdings Channel reports. The fund owned 14,219 shares of the company’s stock after acquiring an additional 2,337 shares during the quarter. Evolve Private Wealth LLC’s holdings in AbbVie were worth $3,092,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ABBV. Vanguard Group Inc. boosted its stake in shares of AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. State Street Corp increased its stake in shares of AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the period. Geode Capital Management LLC increased its stake in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after buying an additional 4,190,487 shares during the period. Bank of America Corp DE raised its holdings in AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after buying an additional 356,394 shares during the last quarter. Finally, Norges Bank bought a new position in AbbVie in the 4th quarter valued at approximately $5,865,055,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

NYSE ABBV opened at $216.63 on Monday. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81. The business has a 50 day moving average price of $212.18 and a 200-day moving average price of $218.72. The company has a market cap of $382.74 billion, a price-to-earnings ratio of 106.71, a P/E/G ratio of 0.66 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the business earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, equities research analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research reports. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target for the company. Guggenheim reiterated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

View Our Latest Research Report on ABBV

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.